retrofitting a new process to an existing facility

2
© Bioproduction Group. All Rights Reserved. 1 GOAL Highly accurate process-based and economic modeling of a number of new technologies as they would perform in the plant New technologies assembled into a library of pre-configured ‘plug-and- play’ unit operations that included detailed operational data Showed the impact of changes to a single unit operation, the plant, and the entire production network Analysis guided a large biopharmaceutical manufacturer in their selection of technologies for future plant build. CASE STUDY BIOPHARMACEUTICAL PLANT OF THE FUTURE TO EvALUATE THE IMPACT OF NEw TECHNOLOGIES IN ExISTING PLANTS AND NEw PLANT DESIGNS. HIGH LEvEL SUMMARY Whether you’re building a new plant or retrofitting an existing one, there are a myriad of technology options available to manufacturers. The recent explosion in disposables, as well as perfusion fermentation, continuous chromatography, inline dilution, and inline testing provide important cost reductions and labor savings as well as improving throughput. However, biopharmaceutical manufacturers have traditionally avoided implementing such new technologies as the ‘cost of getting it wrong’ is very high. Small inaccuracies in throughput calculations (5-20%) can significantly impact the value of a new technology, as seen below. More importantly, this graph suggests that accurately estimating process and throughput calculations is considerably more important than any other single metric. Bio-G’s brief was to evaluate the economic impact of new technologies currently being explored, to enable a large biopharmaceutical manufacturer to target areas where future technology development efforts should be directed. THE BRIEF THE COST OF GETTING IT wRONG: A Comparison Of The Economic Effect Of Calculation Errors NPV ($MM) 20% Deviation 10% Deviation 5% Deviation 40 20 0 -20 -10 10 30 -30 Raw Materials Costs Construction Costs Quantity Produced NPV $35MM)

Upload: gbx-summits

Post on 20-Jan-2017

121 views

Category:

Documents


4 download

TRANSCRIPT

© Bioproduction Group. All Rights Reserved. 1

GOAL

Highly accurate process-based and economic modeling of a number • of new technologies as they would perform in the plant

New technologies assembled into a library of pre-configured ‘plug-and-• play’ unit operations that included detailed operational data

Showed the impact of changes to a single unit operation, the plant, • and the entire production network

Analysis guided a large biopharmaceutical manufacturer in their • selection of technologies for future plant build.

CASE STUDYBIOPHARMACEUTICAL

PLANT OF THE FUTURE

TO EvALUATE THE IMPACT OF NEw TECHNOLOGIES

IN ExISTING PLANTS AND NEw PLANT DESIGNS.

HIGH LEvEL SUMMARY

Whether you’re building a new plant or retrofitting an existing one, there are a myriad of technology options available to manufacturers. The recent explosion in disposables, as well as perfusion fermentation, continuous chromatography, inline dilution, and inline testing provide important cost reductions and labor savings as well as improving throughput.

However, biopharmaceutical manufacturers have traditionally avoided implementing such new technologies as the ‘cost of getting it wrong’ is very high. Small inaccuracies in throughput calculations (5-20%) can significantly impact the value of a new technology, as seen below.

More importantly, this graph suggests that accurately estimating process and throughput calculations is considerably more important than any other single metric. Bio-G’s brief was to evaluate the economic impact of new technologies currently being explored, to enable a large biopharmaceutical manufacturer to target areas where future technology development efforts should be directed.

THE BRIEF

THE COST OF GETTING IT wRONG:A Comparison Of The Economic Effect Of Calculation Errors

NPV ($MM) 20% Deviation10% Deviation5% Deviation

40

20

0

-20

-10

10

30

-30

Raw Materials Costs Construction Costs Quantity Produced

NPV $35MM)

© Bioproduction Group. All Rights Reserved. 2

MORE INFORMATION

BIOPRODUCTION GROUP [email protected] WWW.BIO-G.COM

SCIENCE BASE

Different operations:Equipment Data

Operating CharacteristicsEnergy/UtilityRequirements

PROCESSOPTIMIZATION

Process DescriptionRaw Materials Consumption

Operating TimesUnit Operations

Labor Usage

ANALYSIS

DESIGN

PROCESSANALYSIS ANDPERFORMANCE

Process SchemeResources Consumed

Plant ThroughputCycle Times

FACILITYANALYSIS AND

DESIGN

Capital & Operating CostsDirect & Indirect

HeadcountsEquipment

NEWTECHNOLOGYINNOVATION

FACILITYECONOMICS

Performance Data on areas of improvement

Key risks and performance requirements

Bottle-neck Analysis

HOw wE DID IT

Lee Schruben, Principal

“The critical insight is to realize that you can’t see unit operations in isolation.”

Bioproduction Group’s approach was to build a ‘Plant of the Future’ toolset that would allow rapid evaluation of technology alternatives. “The critical insight is to realize that you can’t see unit operations in isolation”, comments Principal Lee Schruben. “You need to integrate a new technology with existing technologies, and that means a robust understanding of current processes as well.”

Implementing this approach required Bio-G to use existing operational data at the manufacturer to produce datasets for cleaning, media and buffer preparation and other key activities that are common in any biopharmaceutical plant. This data was then combined with the new technology to understand how it would impact the overall plant performance.

Such an approach proved important in establishing an accurate estimate of throughput, and therefore an accurate estimate of cost. Variability in unit operation times was often just as important as the average time, resulting in highly congested facilities with mis-matched unit operations.

RESULTS Bio-G’s ‘Plant of the Future’ toolset created a highly accurate estimate of process fit and economic evaluation of a series of new technologies and possible process platforms. The toolset was used by Engineering, Process Development, Supply Chain and Manufacturing staff to understand the details of new technologies, and how they would fit in the manufacturing network. The approach allowed the manufacturer to show clear benefits to implementing key new technologies, minimizing technology risk and providing a road map for future plant and retrofit scenarios.